ScholarIQanswers from OpenAlex

The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype

PaperCitations, authors & open-access status

The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype is a paper indexed in ScholarIQ from OpenAlex.

How many citations does The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype have?

ScholarIQcitation count

The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype has 133 citations in the OpenAlex counts ScholarIQ stores.

When was The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype published?

ScholarIQyear

The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype has 2017 year in the ScholarIQ index.

What is the open-access status of The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype?

ScholarIQoa status

The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype has bronze oa status in the ScholarIQ index.

What is the DOI of The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype?

ScholarIQdoi

The DOI for The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype is on the source record.

What is the PMID of The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype?

ScholarIQpmid

The PMID for The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype is on the source record.

What is the OpenAlex record for The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype?

ScholarIQopenalex

The OpenAlex for The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial